about
IL-10 regulates Aicda expression through miR-155Mcl-1 is essential for the survival of plasma cells.Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma developmentThe RNA-binding protein HuR is essential for the B cell antibody response.NFκB1 is essential to prevent the development of multiorgan autoimmunity by limiting IL-6 production in follicular B cells.Plasma cell development: from B-cell subsets to long-term survival niches.BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.Assessing Immune-Related Adverse Events of Efficacious Combination Immunotherapies in Preclinical Models of Cancer.Haemopedia: An Expression Atlas of Murine Hematopoietic Cells.The tyrosine kinase Lyn limits the cytokine responsiveness of plasma cells to restrict their accumulation in mice.CD19 differentially regulates BCR signalling through the recruitment of PI3K.Different kinetics of blimp-1 induction in B cell subsets revealed by reporter gene.Gene therapy delivery of myelin oligodendrocyte glycoprotein (MOG) via hematopoietic stem cell transfer induces MOG-specific B cell deletion.The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death.Initiation of plasma-cell differentiation is independent of the transcription factor Blimp-1.Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.Identification of a Siglec-F+ granulocyte-macrophage progenitor.BAFF-driven autoimmunity requires CD19 expression.Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.Transcriptional profiling of eosinophil subsets in interleukin-5 transgenic mice.FcγRIIb controls bone marrow plasma cell persistence and apoptosisTargeting malignant B cells as antigen-presenting cells: TLR-9 agonist induces systemic regression of lymphomaFluorescent antibiotics, vomocytosis, vaccine candidates and the inflammasome
P50
Q28251207-F0B5A07C-3863-4A47-B44C-A7C91593CBC2Q30412677-19049709-8E3E-44E6-B81F-98C5BC30CB7AQ34192011-2717B8F5-B2EF-4EF2-AE0F-4B81FE9030B7Q35776191-A12611EA-71D6-4E5B-8A03-0A4EE9C6AEE7Q36767459-745C2318-9C26-4C02-B088-92DA2287FB37Q37068273-049AED3E-58F5-40B1-AB59-5D9CD54E5389Q38013996-8D59B055-62C5-49F4-A31D-47E065A010F8Q38752932-F94BD637-EB8A-4A7F-9B6E-89501BBAADF5Q39515020-C68268E6-3BAB-4248-817E-9A411081E863Q43697917-D8106196-2AAE-412F-BE6B-F5F6B0952BCFQ45299837-68DFBA32-4037-40BD-AB3E-C303176495E1Q45304582-6E34D914-C01C-43AF-9811-3238BA0DAE20Q45862484-CBDE8A1A-088B-44AE-BD91-CE2884891327Q46193158-84CD3C7C-7CF7-4FA5-A568-F369AB1EA7D8Q50900427-1058788C-08CF-4ABE-AC7A-F384A72D7A73Q51666176-D40B05BE-A03A-4BE8-A0FE-0C38B5B01951Q52719869-1538049F-FF43-4E7B-B7EC-5DFDD06C57B1Q52935473-F17AC107-00C6-47BC-A40E-C7B9546FE689Q52939927-DA87592F-4271-42EE-BC1F-438656EC719AQ54212582-8CC162F5-369C-47DB-B97D-7AE174B77346Q60268649-8FD54E19-8118-4F70-A6AC-BF6A6440FB13Q83703093-FA035317-71BE-499B-BE3C-AAEE9644B22FQ91176480-5D0D0B5F-0256-4A1A-A34F-06BC1092ABB4
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-8394-137X
@en
name
Kirsten A Fairfax
@ast
Kirsten A Fairfax
@en
Kirsten A Fairfax
@es
Kirsten A Fairfax
@nl
type
label
Kirsten A Fairfax
@ast
Kirsten A Fairfax
@en
Kirsten A Fairfax
@es
Kirsten A Fairfax
@nl
prefLabel
Kirsten A Fairfax
@ast
Kirsten A Fairfax
@en
Kirsten A Fairfax
@es
Kirsten A Fairfax
@nl
P106
P1153
16067986500
P31
P496
0000-0002-8394-137X